- People
- Offices
- Capabilities
back- Capabilities
- Corporate, Finance and Investments
- back
- Corporate, Finance and Investments
- Overview
- Activist Defense
- Capital Markets
- Construction and Procurement
- Corporate Governance
- Emerging Companies and Venture Capital
- Employee Benefits and Executive Compensation
- Energy and Infrastructure Projects
- Financial Restructuring
- Fund Finance
- Global Human Capital and Compliance
- Investment Funds and Asset Management
- Leveraged Finance
- Mergers and Acquisitions (M&A)
- Middle East and Islamic Finance and Investment
- Private Credit & Special Situations
- Private Equity
- Public Companies
- Real Estate
- Structured Finance and Securitization
- Tax
- Technology Transactions
- Government Matters
- back
- Government Matters
- Overview
- Antitrust
- Data, Privacy and Security
- Environmental, Health and Safety
- FDA and Life Sciences
- Government Advocacy and Public Policy
- Government Contracts
- Healthcare
- Innovation Protection
- International Trade
- National Security and Corporate Espionage
- Securities Enforcement and Regulation
- Special Matters and Government Investigations
- Trial and Global Disputes
- back
- Trial and Global Disputes
- Overview
- Antitrust
- Appellate, Constitutional and Administrative Law
- Bankruptcy and Insolvency Litigation
- Class Action Defense
- Commercial Litigation
- Construction and Engineering Disputes
- Corporate and Securities Litigation
- E-Discovery
- Innovation Protection
- Intellectual Property
- International Arbitration and Litigation
- Labor and Employment
- Product Liability
- Professional Liability
- Toxic & Environmental Torts
- Industries / Issues
- back
- Industries / Issues
- Automotive, Transportation and Mobility
- Energy Transition
- Energy
- Financial Services
- Food and Beverage
- Higher Education
- Life Sciences and Healthcare
- Technology
- #MeToo
- Artificial Intelligence (AI) and Machine Learning
- Buy American
- Crisis Management
- Doing Business in Latin America
- Environmental Agenda
- Environmental, Social and Governance (ESG)
- Focus on Women's Health
- Russia/Ukraine
- Special Purpose Acquisition Companies (SPACs)
- Careers
- News & Insights
- About
- Languages
Gillian M. Russell
News 1 results
Press Release
November 8, 2016
King & Spalding Promotes Eight Counsel in Three Offices
Events 22 results
Webinar
January 29, 2025
Summary of FDA’s New Final Guidance: Scientific Information on Unapproved Uses
Webinar
January 22, 2025
Year in Review for Drug and Device Advertising and Promotion
Speaking Engagement
October 16, 2024
Gillian Russell to Speak at FDLI’s Introduction to Advertising and Promotion for Medical Products Conference
Speaking Engagement
October 8, 2024
Nikki Reeves and Gillian Russell to Speak at the Seton Hall Compliance Congress
Insights 18 results
Client Alert
January 13, 2025
FDA Finalizes Guidance on Scientific Information on Unapproved Uses (SIUU)
Article · Source: The Legal 500
December 10, 2024
The Legal 500 Country Comparative Guides: United States Pharmaceutical Advertising
Client Alert
July 12, 2024
FDA Issues Updated Draft Guidance on Addressing Misinformation About Medical Devices and Prescription Drugs